2022 Juli: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics sareng GenScript ProBio nuju dina prosés nandatanganan kontrak pikeun ngembangkeun sareng produksi plasmid sareng véktor virus pikeun pipa munggaran tina ACT Therapeutics 'Advanced CAR-T Platform (platform ACT), anu ogé bakal ditugaskeun pikeun ngahasilkeun bahan baku. pikeun saluran pipa salajengna ACT Therapeutics. Kontrak éta bakal nutupan produksi plasmid sareng véktor virus pikeun jalur pipa munggaran tina ACT Therapeutics 'Advanced CAR-T Platform.
Salaku hasil tina perjangjian ieu, GenScript ProBio parantos diangkat kana status pasangan global anu tiasa ngadukung platform ACT pikeun terapi ACT.
Platform ACT mangrupikeun téknologi terapi sél sareng gén generasi salajengna anu nargétkeun antigén kanker ku cara nyelapkeun gén anu dirancang pikeun nargétkeun antigén éta kana sél imun. Gén ieu dikirimkeun kana sél imun ngaliwatan pamakéan véktor virus. GenScript ProBio gaduh pamekaran prosés vektor virus anu kualitas luhur sareng platform layanan sapinuhna pikeun produksi GMP, duanana dipikabutuh pikeun ngembangkeun terapi sél sareng gén.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing kanker getih. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO GenScript ProBio, nyarios, "Kami bagja pisan pikeun gawé bareng terapi ACT dina kemitraan strategis, sareng kami ngarepkeun ngadukung platform ACT Therapeutics salaku mitra global ngaliwatan téknologi akumulasi kami."
Seogkyoung-Kong, CEO ACT Therapeutics, nyarios, "Kami parantos réngsé persiapan pikeun platform ACT muncul sacara global ngaliwatan kerjasama strategis sareng GenScript ProBio. Kami bakal ngagancangkeun pamekaran pangobatan anu nargétkeun kanker padet anu refraktori sareng teu tiasa dicabut.
Ngeunaan GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Nuju misi "Inovasi ngaliwatan Kolaborasi", GenScript ProBio komitmen pikeun mantuan konsumén shorten timeline pikeun ngembangkeun ubar biologis ti kapanggihna kana commercialization, nyata nurunkeun biaya R&D sarta ngawangun masa depan healthier.
